VRDN240719C25000
- 0.10
- 0.000.00%
Viridian Therapeutics Newsroom
Viridian Therapeutics Shares Rise on Patient Demand for Thyroid Eye Disease Clinical Trial
Express News | Viridian Therapeutics Inc - Thrive-2 Topline Data Readout on Track for Year-End 2024
Express News | Viridian Therapeutics Announces Completion of Thrive-2 Enrollment for Vrdn-001 in Patients With Chronic Thyroid Eye Disease (Ted)
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $35
RBC Capital analyst Gregory Renza maintains $Viridian Therapeutics(VRDN.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 45.6
Buy Rating for Viridian Therapeutics on VRDN-001 Clinical Advancements and Market Potential
Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn Into More Strength?
Viridian Therapeutics Up Over 14%, on Pace for Largest Percent Increase Since January 2023 -- Data Talk
Viridian, Pharvaris Said to Be Among Prime M&A Targets for Biogen
HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $27 Price Target
BTIG Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $46
BTIG analyst Julian Harrison maintains $Viridian Therapeutics(VRDN.US)$ with a buy rating, and maintains the target price at $46.According to TipRanks data, the analyst has a success rate of 56.3%
H.C. Wainwright Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $27
H.C. Wainwright analyst Douglas Tsao maintains $Viridian Therapeutics(VRDN.US)$ with a buy rating, and maintains the target price at $27.According to TipRanks data, the analyst has a success rate of 4
Buy Rating for Viridian Therapeutics Amidst Promising Thyroid Eye Disease Drug Trials
LifeSci Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $46
LifeSci Capital analyst Rami Katkhuda maintains $Viridian Therapeutics(VRDN.US)$ with a buy rating, and maintains the target price at $46.According to TipRanks data, the analyst has a success rate
Buy Rating Affirmed for Viridian Therapeutics Amid Promising TED Treatment Advancements
Viridian Therapeutics Releases Updated Investor Presentation
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $42
Wedbush analyst Laura Chico maintains $Viridian Therapeutics(VRDN.US)$ with a buy rating, and maintains the target price at $42.According to TipRanks data, the analyst has a success rate of 47.9%
Optimistic Outlook for Viridian Therapeutics With Multiple Clinical Milestones Ahead
Express News | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now?
Ladenburg Thalmann Maintains Viridian Therapeutics(VRDN.US) With Hold Rating
Ladenburg Thalmann analyst Michael Higgins maintains $Viridian Therapeutics(VRDN.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 34.3% and a total average return